The introduction of nicotinamide for a nicotine alternative in e-cigarette and smokeless solutions represents a substantial regulatory obstacle for the FDA. Nicotinamide does not have nicotinic receptor agonist activity and is understood to work as a sedative at superior dosages6. The statements made by Nicotine River, ECBlend, together with other